Hormone therapy (HT) is associated with an increased risk of venous thromboembolism (VTE), but can statins (often used concurrently with HT in postmenopausal women) reduce this occurrence? Cases of VTE were evaluated in a nested case-control study of a population-based cohort of 955,582 women ages 50–79 years of age from the UK General Practice Research Database between January 1, 1987 and March 1, 2008. Use of statins was linked to a decreased risk of VTE, regardless of any HT use (OR, 0.83; 95% CI, 0.78–0.87). The risk of VTE was higher with oral estrogen and progestogen combinations among nonstatin users (OR, 1.55; 95% CI, 1.45–1.66) but concurrent statin and HT use was borderline significant (P=0.053), with no increased VTE risk seen among these patients. Because statins could decrease this risk associated with oral estrogens and progestogens, additional research should be conducted in large cohorts, the authors emphasize.
Objective: Statins and hormone therapy (HT), often used concurrently in postmenopausal women, have antagonist effects on the risk of venous thromboembolism (VTE). Methods: We conducted a nested case-control study within a population-based cohort of women aged 50–79 years between January 1, 1987 and March 1, 2008, who were identified from the UK General Practice Research Database.
READ FULL ARTICLE
From Lww
Please login or register first to view this content.
